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Abstract  Even  with  improvements  in  lifestyle  interventions,  better  control  of  cardiovascular
(CV) risk factors,  and  improvements  in CV  outcomes,  cardiovascular  disease  (CVD)  remains  the
leading cause  of  morbidity  and  mortality  in  Portugal  and Europe.  Atherogenic  dyslipidemias,
particularly  hypercholesterolemia,  have  a  crucial  causal  role  in the  development  of  atheroscle-
rotic CVD.  The  clinical  approach  to  a  patient  with  dyslipidemia  requires  an  accurate  diagnosis,
based on harmonized  and  standardized  lipid  and lipoprotein  laboratory  assessments.  Results  and
reports of  these  tests,  together  with  assessment  of  total  CV  risk  and  the  respective  therapeutic
targets, will  help  ensure  that  clinical  guidelines  and  good  clinical  practices  are  followed,
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increasing  the  reliability  of  screening  for  lipid  disorders,  producing  more  accurate  diagnoses  and
CV risk  stratiﬁcation,  and  improving  CV  prevention.  To  this  end,  this  consensus  aims  to  provide
clinicians  with  practical  guidance  for  the  harmonization  and  standardization  of  laboratory  lipid
tests, focusing  on the  most  recent  dyslipidemia  management  guidelines.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
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Padronizac¸ão  da  avaliac¸ão  laboratorial  do  perﬁl  lipídico:  um  apelo  à  ac¸ão  com  foco
especial  nas  recomendac¸ões europeias  de dislipidemia  da  ESC/EAS  de  2016 -- sumário
executivo
Um  consenso  endossado  pelo  Grupo  de  Prevenc¸ão  e  Risco  Cardiovascular
da  Sociedade  Portuguesa  de  Medicina  Interna,  Sociedade  Portuguesa  de  Cardiologia,
Sociedade  Portuguesa  de Medicina  Laboratorial  e  Associac¸ão Portuguesa  de  Analistas
Clínicos
Resumo  Apesar  da  melhor  intervenc¸ão  nos  estilos  de  vida,  do  melhor  controlo  dos  fatores
de risco  cardiovascular  (CV)  e da  melhoria  dos  resultados  CV,  a  doenc¸a  cardiovascular  (DCV)
continua  a  ser  a  principal  causa  de  morbilidade  e  mortalidade  em  Portugal  e na  Europa.
A dislipidemia  aterogénica,  nomeadamente  a  hipercolesterolemia,  tem  um  papel  causal  no
desenvolvimento  de DCV  aterosclerótica.  A abordagem  clínica  de  um  doente  com  dislipidemia
preceitua um  diagnóstico  atento,  sustentado  em  procedimentos  laboratoriais  harmonizados  e
padronizados.  Os  resultados  e  relatórios  dos  testes  de lipídios  se  ajuntarem  o risco  CV  total  e
os respetivos  alvos  terapêuticos  garantem  que  as  diretrizes  clínicas  e  as  boas  práticas  clínicas
estão a  ser  seguidas  e  respeitadas,  o que  aumenta  a  seguranc¸a  no  rastreio  e no  diagnóstico  das
alterac¸ões lipídicas  e da  estratiﬁcac¸ão  de risco  e  melhora  a  prevenc¸ão  CV.  Nesse  sentido,  este
consenso tem  como  objetivo  fornecer  aos  clínicos  orientac¸ões  práticas  para  a  harmonizac¸ão
e padronizac¸ão  dos  testes  laboratoriais  lipídicos,  com  foco  nas  diretrizes  mais  recentes  da
abordagem das  dislipidemias.
©  2018  Sociedade  Portuguesa  de Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
Cardiovascular  disease  (CVD)  remains  one  of  the  leading
causes  of  morbidity  and  mortality  worldwide.1,2 In  Portugal,
diseases  of  the circulatory  system  accounted  for  29.5%
of  deaths  recorded  in 2013,  with  a  mortality  of  54.6  per
100  000  for  cerebrovascular  disease  and  of  32.9  per  100  000
for ischemic  heart  disease.3
Atherogenic  dyslipidemias,  particularly  hypercholes-
terolemia,  play  an unquestionable  role  in the development
of  atherosclerotic  CVD.  Accurate  and timely  diagnosis  of
dyslipidemia  is  of  crucial  importance.  For this  diagnosis,
it  is  essential  to obtain  an  accurate  laboratory  assessment
of  the  patient’s  lipid  proﬁle.  This  information,  combined
with  thorough  clinical  history  collection  and  physical
examination,  can be  used  to  determine  the  patient’s  CV
risk,  a  key  tool  in therapeutic  management.4 The  intensity
of  risk-reduction  therapy  should  generally  be  adjusted
to  the  patient’s  absolute  risk  for  a  CVD  event. Appro-
priate  screening,  prevention,  diagnosis,  monitoring  and
treatment,  combined  with  an  accurate  and  standardized
laboratory  diagnosis,  are essential  to  the  management  of
dyslipidemias  and  CVD  prevention  in clinical  practice.
In  Portugal,  a  need  has  been  identiﬁed  to  harmo-
nize various  aspects  of  laboratory  lipid  measurements.  A
meeting  with  specialists  in clinical  pathology,  laboratory
medicine,  clinical  analysis,  cardiology,  internal  medicine
and  endocrinology  was  held  with  the  purpose  of  prepar-
ing  nationwide  recommendations  for  lipid  proﬁle  assessment
and  reporting  in adult  patients,  based  on  the  latest  guide-
lines  for  CVD  prevention  and  treatment.  The  recommen-
dations  presented  herein  reﬂect  the  debate  and  consensus
reached  by  this expert  panel.  This  proposal  reﬂects  the
most  recent  European  guidelines  on  CVD  prevention5 and  the
management  of  dyslipidemias.4 They  should serve  as  a  foun-
dation  for  standardizing  lipid  assessment  strategies,  as  well
as  laboratory  lipid  assessment  reports,  in  all  national  clinical
analysis  laboratories.  These  recommendations  are  divided
into  four  main  topics:  CVD  prevention  and  treatment  guide-
lines;  dyslipidemia  screening;  lipid  biomarker  assessment;
and reporting  of  laboratory  lipid  assessments.
Cardiovascular  disease prevention
and treatment  guidelines
There  are various  national  and  international  guidelines  on
the  prevention  and  treatment  of  CVD.  This  expert  panel
recommends  adopting  the recommendations  of  the Euro-
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pean  Atherosclerosis  Society  (EAS)  and European  Society
of  Cardiology  (ESC) for  the  management  of  dyslipidemias4
and  for  CVD  prevention  in clinical  practice,5 and  following
the  three  speciﬁc  standards  of  good clinical  practice (GCP)
published  by  the  Portuguese  Directorate-General  of  Health
(DGS)  on  this  matter,6--8 speciﬁcally  in terms  of CVD  risk
stratiﬁcation  and  target  lipid  values.  These  GCP  standards
from  the  DGS  should be  sources  of  guidance  and  instruments
of  clinical  decision  support  in  the  National  Health  Service  to
promote  the  development  of  excellence  in  health  care  and
its  evaluation  in the hospital  network,  health  centers,  family
health  units  and  continuous  care.
We  advocate  appropriate  screening,  diagnosis,  monitor-
ing  and  treatment  of  dyslipidemias,  as  a crucial  part  of  CVD
prevention  in  clinical  practice.  For assessment  of total  CV
risk,  we  support  the SCORE  risk  chart  for  determination  of
10-year  risk  of a  ﬁrst fatal  atherosclerotic  CV  event (e.g.
myocardial  infarction,  stroke  or  other  occlusive  arterial  dis-
ease,  including  sudden  cardiac  death),  in apparently  healthy
people  with  no recognized  CVD.  Individuals  with  a history  of
a  CV  event,  type  1 or  2  diabetes,  very  high  levels  of individ-
ual  risk  factors  (e.g.  familial  hypercholesterolemia  or  blood
pressure  ≥180/110  mmHg),  or  chronic  kidney  disease,  have
very  high  or  high  total  CV risk  and no  further  risk  estimation
is  required.
The SCORE  data  indicate  that  total  risk  for CV  events
is  about  three  times  higher  than  the  risk  of  fatal CVD  in
men,  and  four  times  higher  in women,  but  somewhat  less  in
the  elderly.  In older  patients  the likelihood  of  a  ﬁrst  fatal
CV  event  is  naturally  higher.  In  older  people  (>60  years  of
age),  the  SCORE  risk  threshold  should  not  be  applied  strictly,
because  their  age-speciﬁc  risk  is  normally  around  these  lev-
els,  even  when  other  CV  risk  factor  levels  are  normal.
Young  people  with  high  levels  of risk  factors  deserve
particular  consideration.  Lifetime  risk  is  probably  the best
approach  to evaluate  the impact  of  risk  factors  in this popu-
lation,  but  there  are  still  insufﬁcient  epidemiological  cohort
data  to  support  its  application.  In young  people,  an esti-
mate  of their  relative  risk  --  rather  than their  absolute  risk,
which  is  presumably  low --  or  the  use  of  ‘CV  risk  age’  may
be  helpful.4
Recommendations for the screening
of  dyslipidemia
Screening  for  dyslipidemia  is  indicated  in all  adults  (men
aged  ≥40  years  and  women  aged  ≥50  years  or  post-
menopausal),  particularly  in the presence  of other  classic  CV
risk  factors;  in patients  with  clinical  CVD  (secondary  preven-
tion)  or  with  clinical  conditions  associated  with  increased
CV  risk  (primary  prevention),  especially  in patients  with
obesity,  metabolic  syndrome  and/or  diabetes;  and  in HIV-
infected  patients  (Table  1, adapted  from9). It  is  also
recommended  to  screen  offspring  of  patients  with  severe
dyslipidemia  and  family  members  of  patients  with  prema-
ture  CVD.
The  rationale  of  CVD  risk  assessment  is  to  convince  indi-
viduals  without  treatable  risk  factors  and  low CV  risk  to
maintain  a  healthy  lifestyle,  to  recommend  individuals  with
treatable  CV  risk  factors  or  unhealthy  behaviors  to  mod-
ify  their  attitudes  and  to  treat  and  manage  modiﬁable  risk
Table  1  Who  to  screen  for  dyslipidemia  in  adults  at  risk.
All  patients  with  these  conditions
regardless  of  age:
Men  aged  ≥40
years  of  age  and
women  aged  ≥50
years  (or
postmenopausal)
• Clinical  evidence  of  CVD
• Abdominal  aortic  aneurysm
• Diabetes
• Hypertension
• Current  cigarette  smoking
• Stigmata  of  dyslipidemiaa
• Family  history  of  premature  CVDb
• Family  history  of  dyslipidemia
• CKD
• Obesity  (BMI  ≥30  kg/m2)
• IBD  and  other  inﬂammatory
disorders
• HIV  infection
• Erectile  dysfunction
• COPD
• Hypertensive  disease  or  diabetes
in pregnancy
a Arcus corneae, xanthelasma or xanthoma.
b Men aged <55 years and women aged <65 years in a ﬁrst-
degree relative.
BMI: body mass index; COPD: chronic obstructive pulmonary dis-
ease; CVD: cardiovascular disease; CKD: chronic kidney disease;
HIV: human immunodeﬁciency virus; IBD: inﬂammatory bowel
disease.
factors,  and  to  identify  subjects  who  will likely  derive  most
beneﬁt  from  pharmacotherapy  and concomitant  lifestyle
interventions.
We recommend  that  CV  risk  reduction  should  be individu-
alized  and  treatment  goals  should  be identiﬁed.  Low-density
lipoprotein  cholesterol  (LDL-C)  is the  primary  treatment  tar-
get,  but  total  cholesterol  (TC)  can be accepted  if other  lipid
parameters  are  not  available.  Non-high-density  lipoprotein
cholesterol  (non-HDL-C)  and/or  apolipoprotein  B (ApoB)  can
be  used as  secondary  treatment  targets.  We  strongly  suggest
that lipid  treatment  goals  take  total  CV risk  into  consider-
ation.  LDL-C  treatment  targets  should  be:
•  For  low-  and  moderate-risk  individuals:  <115  mg/dl  (<3.0
mmol/l)
•  For  high-risk  patients:  <100  mg/dl  (<2.6  mmol/l),  or  a
reduction  of  at least  50%  if baseline  LDL-C  is  between  100
and  200 mg/dl  (2.6-5.2  mmol/l).
•  For  very  high-risk  patients:  <70  mg/dl  (<1.8  mmol/l)  or  a
decrease  of at least  50%  if  baseline  LDL-C  is  between  70
and  135 mg/dl  (1.8-3.5  mmol/l).
The diagnosis  of  dyslipidemia  should always  be conﬁrmed
by subsequent  laboratory  assessment  of  lipid  proﬁle,  carried
out  in a  minimum  of  four weeks,  prior  to  the  beginning  of
any  pharmacological  therapy  (in  line  with  the  DGS’s  standard
no.  019/2011).6
The  frequency  of testing  depends  on  the  person’s  CV
risk  proﬁle.  After  4-12  weeks  from  the start of  drug treat-
ment  a second  fasting  lipid  panel  should  be  performed.
Subsequently,  assessments  should  be performed  every  three
months  until  the lipid  goals  are achieved,  and  thereafter
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every  12  months,  as  clinically  indicated.  However,  when  LDL-
C  lowering  therapy  is  adapted  (e.g.  any  intensiﬁcation  of
lifestyle  interventions,  titration  of  statin  therapy,  or  adding
of  non-statin  therapies),  we  recommend  a new  lipid  panel,
again  4-12  weeks  after treatment  adjustment,  followed  by
resumption  of  the  above  regimen.
Recommendations for  lipid  biomarker
assessment
We recommend  that  a  baseline  lipid  assessment  should
include  estimation  of TC, triglycerides  (TG),  high-density
lipoprotein  cholesterol  (HDL-C),  LDL-C (calculated  with  the
Friedewald  formula,  based  on  fasting  plasma  TC,  TG,  and
HDL-C  values,  or  determined  directly),  and non-HDL-C.
Fasting  and  non-fasting  lipid  levels  have  similar  prediction
strength  and should  be  regarded  as  complementary.  Non-
fasting  lipid levels  can  be  applied  in screening  and  risk
estimation;  however,  in general,  a 12-hour  fasting  period
is  still  considered  optimal  when lipoprotein  measurements
are  used  in  CV  risk  screening  and  estimation  and for charac-
terizing  dyslipidemias  before  treatment.
We  are  aware  of  the  signiﬁcant  limitations  of the
Friedewald  formula.10,11 Its  estimates  are not  valid  when
TG  >400  mg/dl  (>4.5  mmol/l),  in  patients  with  type
III hyperlipoproteinemia  (dyslipidemia  with  accumulation
of  cholesterol-rich  remnants)  or  chylomicronemia,  or  in
nonfasting  specimens.  Recently,  novel  LDL-C  estimation  for-
mulas  such  as  (non-HDL-C)  -  (TG/adjustable  factor  mg/dl)
have  been  proposed,12 in which an adjustable  factor  was
established  as  the strata-speciﬁc  median  TG:very  low  den-
sity  lipoprotein  cholesterol  (VLDL-C)  ratio. Although  this new
method  appears  to  provide a  better  estimate  of LDL-C (par-
ticularly  in  patients  with  LDL-C  ≤70 mg/dl in the presence
Table  2  Indications  for  Lp(a)  screening.
• Premature  CVD
• Familial  hypercholesterolemia
• Family  history  of  premature  CVD  and/or  elevated  Lp(a)
• Recurrent  CVD  despite  optimal  lipid-lowering  therapy
• ≥5%  10-year  risk  of  fatal  CVD  according  to  SCORE
• Hemodialysis  and  CKDa
• Intermediate  (3-5%)  10-year  risk  of fatal  CVD
according  to  SCOREa
a Possible indications for Lp(a) determination, but not clearly
stated in the current international guidelines.
CVD: cardiovascular disease; CKD: chronic kidney disease; Lp(a):
lipoprotein(a); SCORE: Systematic COronary Risk Evaluation.
of  high  TG  levels),  it  needs  to  be  more  widely  validated,
and  the  formula  selected  in  each  laboratory  determination
should  be clearly  stated.
If  available,  and in particular  clinical  circumstances,
ApoB  and lipoprotein(a)  (Lp(a))  can  also  be estimated.
Non-HDL-C  is  an umbrella  term  for  all  plasma  atherogenic
lipoproteins  (VLDL,  VLDL  remnants,  intermediate-density
lipoproteins,  LDL,  and  Lp(a)).  It is  calculated  as  TC minus
HDL-C,  and is  associated  with  ApoB  levels.  A  powerful  CV  risk
predictor,  non-HDL-C  is  simple  to  compute  and  does  not  need
fasting  conditions.13 This  is  the reason  for including  non-
HDL-C,  unlike  ApoB,  in  the standard  lipid  proﬁle  assessment.
Measurement  of Lp(a)  is  not  currently  recommended,  and
should only be performed  in  speciﬁc  patients4,14,15 (Table  2).
CV  risk  is  signiﬁcant  when Lp(a) >50 mg/dl.  In patients  at
risk  with  high  Lp(a)  levels  the  treatment  of modiﬁable  CV
risk  factors  should  be intensiﬁed,  particularly  LDL-C  (with
intensive  lipid-lowering  therapy).  The  effect  on  CVD  events
of  targeting  Lp(a) has  not  been  established  and  Lp(a)  should
not  be  a  lipid  target  in CV  prevention.
Figure  1 A  possible  example  of  a  laboratory  lipid  test  report.
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Recommendations for the reporting
of  laboratory  lipid  assessments
The  expert  panel  recommends  including  the  methods  used
for  lipid  biomarker  quantiﬁcation,  as  well  as  the speciﬁc
equipment  employed  to  that  end  and  the  associated  varia-
tion  coefﬁcients,  in all  laboratory  lipid  reports.
We  strongly  emphasize  the  importance  of  lipid  test
reports  including  speciﬁc  information  on  target  LDL-C  val-
ues,  according  to  the different  CV risk  levels  (<70  mg/dl,
<100  mg/dl  and  <115  mg/dl),  in line  with  the  DGS’s  standard
no.  005/2013.8 This  should  be  accompanied  by  a  suppor-
ting  statement,  such  as ‘‘CV  risk  to  be  determined  by  the
attending  physician’’  (Figure  1). We  also  propose  that  lab-
oratory  reports  should  ﬂag nonstandard  lipid values  based
on  desirable  concentration  cut-points,  deﬁned  by  guidelines
and  consensus  statements.4,5,9,16
Final word
Atherosclerotic  CVD  is  preventable.  We  and our  scientiﬁc
societies  wish  to  promote  the best  health  care  for individuals
of  both  sexes  and all  ages  who  are  at CV  risk.  We  are  aware
that  effective  CV prevention  is  frequently  overlooked  in our
daily  practice.  CV prevention  is  in fact  an  ethical  obligation.
It  is important  to  recognize  CV  risk,  to  stress  the importance
of  laboratory  reports,  and  to  identify  clinical  situations  that
warrant  judicious  intervention.
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